In a clinical whole-exome sequencing study focusing on neurodevelopmental disorders, four patients with de novo missense variants of SUPT16H and one patient with a de novo deletion of SUPT16H were identified (Bina et al., 2020). Here, SUPT16H is linked to neurodevelopmental disorder.